News

Oxygen Biotherapeutics said that Dermacyte Oxygen Concentrate is the first product in a cosmetic line which is presently under development. It uses the company’s patented Oxycyte technology, an

The parties to the agreement are: California-based AMC, Hong Kong-based Delta Group Investments (DGI) and Washington-based TNS. AMC is a highly experienced direct mail marketing company. DGI is

MoxDuo CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain. In accordance with the recently approved IND

Melior Discovery has developed expertise in screening compounds for potential therapeutic activity in animal models. Melior is expected to apply this expertise to the evaluation of large numbers

The GI panel provides physicians with accurate test results in one day by which patients can be more effectively treated through targeted therapeutics which reduces overall medical costs

Furthermore Movianto said that it would continue the existing successful cooperation in France. Alongside the storage and distribution of Daiichi Sankyo’s products, Movianto is also expected to be

The study results included demonstration that lymphocyte counts in the vascular space were reduced in a dose-related fashion. As such, Lpath achieved an objective established by Merck KGaA

Sage and Merck are expected to collaborate to create network-based computational models of disease that will contribute to Merck’s drug development strategy. Merck is expected to provide financial

The new contract, which becomes effective April 1, 2010, continues Siemens’ long-standing relationship with Premier, providing members ongoing access to Siemens’ comprehensive portfolio of diagnostic systems, tests, and